Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Robert Cohen who wrote (1382)	5/30/2001 2:50:56 AM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 1477

No, I don’t think so. But, you did miss point from start: Message 15856112 <<In addition since current treatment relies upon multiple drugs, testing this drug only against IV NTG does not tell the whole story.>> Natrecor is not drug with single mechanism of action like diuretic, vasodilator (ACE or NTG), beta blockers, or inotropic (dubutamine), so it does not compete separately with each one. It does work in synergy with ACE and diuretics better than dobutamine or NTG. N benefit in acute PE (mild to severe cases) is apparent, and main contributions are: -dilate veins and arteries, vasodilator -stimulate the kidney to excrete excess fluid, diuretic, -neutralize negative from excessive and harmful hormone secretion. I will suggest that you read first AC transcript, last one (when it become available in few days), as well literature on N. It may help. Miljenko PS: I mentioned early that N will have hard time to penetrate market, and you are good example why.